び漫性に胆管および胆嚢壁肥厚像を呈したNivolumab関連胆管炎の1例
症例は81歳の女性.肺癌に対しNivolumab投与中に肝胆道系酵素上昇と腹部エコーで胆嚢壁肥厚を認め精査目的に当科紹介された.造影CTではび漫性に胆管および胆嚢に濃染する壁肥厚所見を認めたが胆嚢の緊満感はなく,肝内胆管拡張も認めなかった.EUSでは胆管および胆嚢のび漫性壁肥厚所見を認めたが狭窄所見は認めなかった.ERCP胆管像も狭窄所見は認めず,endoscopic nasobiliary drainage tube留置も肝胆道系酵素は改善しなかった.肝生検および胆管生検の病理所見では胆管上皮に好中球浸潤が目立っていたが,悪性所見は認めなかった.Nivolumabによる免疫関連性有害事象と判...
Saved in:
Published in | Tando Vol. 32; no. 1; pp. 132 - 138 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | Japanese |
Published |
日本胆道学会
2018
Japan Biliary Association |
Subjects | |
Online Access | Get full text |
ISSN | 0914-0077 1883-6879 |
DOI | 10.11210/tando.32.132 |
Cover
Abstract | 症例は81歳の女性.肺癌に対しNivolumab投与中に肝胆道系酵素上昇と腹部エコーで胆嚢壁肥厚を認め精査目的に当科紹介された.造影CTではび漫性に胆管および胆嚢に濃染する壁肥厚所見を認めたが胆嚢の緊満感はなく,肝内胆管拡張も認めなかった.EUSでは胆管および胆嚢のび漫性壁肥厚所見を認めたが狭窄所見は認めなかった.ERCP胆管像も狭窄所見は認めず,endoscopic nasobiliary drainage tube留置も肝胆道系酵素は改善しなかった.肝生検および胆管生検の病理所見では胆管上皮に好中球浸潤が目立っていたが,悪性所見は認めなかった.Nivolumabによる免疫関連性有害事象と判断しステロイドを投与し,肝胆道系酵素の改善および胆管と胆嚢壁肥厚所見の改善を認めた.Nivolumab関連胆管炎の特徴的な画像所見を呈した1例と考えられた. |
---|---|
AbstractList | 要旨 : 症例は81歳の女性. 肺癌に対しNivolumab投与中に肝胆道系酵素上昇と腹部エコーで胆嚢壁肥厚を認め精査目的に当科紹介された. 造影CTではび漫性に胆管および胆嚢に濃染する壁肥厚所見を認めたが胆嚢の緊満感はなく, 肝内胆管拡張も認めなかった. EUSでは胆管および胆嚢のび漫性壁肥厚所見を認めたが狭窄所見は認めなかった. ERCP胆管像も狭窄所見は認めず, endoscopic nasobiliary drainage tube留置も肝胆道系酵素は改善しなかった. 肝生検および胆管生検の病理所見では胆管上皮に好中球浸潤が目立っていたが, 悪性所見は認めなかった. Nivolumabによる免疫関連性有害事象と判断しステロイドを投与し, 肝胆道系酵素の改善および胆管と胆嚢壁肥厚所見の改善を認めた. Nivolumab関連胆管炎の特徴的な画像所見を呈した1例と考えられた. An 81-year-old woman, who was treated with nivolumab monotherapy, was referred to our department because of high levels of biliary tract enzymes, detected on performing a blood test. Computed tomography and endoscopic ultrasound showed diffuse wall thickening of the bile duct and gallbladder. Endoscopic retrograde cholangiography revealed extrahepatic bile duct dilation without obstruction. Nivolumab-induced cholangitis was diagnosed and she received steroid therapy. After steroid therapy, both the levels of biliary tract enzymes in blood and the diffuse wall thickening of the bile duct and gallbladder decreased. 症例は81歳の女性.肺癌に対しNivolumab投与中に肝胆道系酵素上昇と腹部エコーで胆嚢壁肥厚を認め精査目的に当科紹介された.造影CTではび漫性に胆管および胆嚢に濃染する壁肥厚所見を認めたが胆嚢の緊満感はなく,肝内胆管拡張も認めなかった.EUSでは胆管および胆嚢のび漫性壁肥厚所見を認めたが狭窄所見は認めなかった.ERCP胆管像も狭窄所見は認めず,endoscopic nasobiliary drainage tube留置も肝胆道系酵素は改善しなかった.肝生検および胆管生検の病理所見では胆管上皮に好中球浸潤が目立っていたが,悪性所見は認めなかった.Nivolumabによる免疫関連性有害事象と判断しステロイドを投与し,肝胆道系酵素の改善および胆管と胆嚢壁肥厚所見の改善を認めた.Nivolumab関連胆管炎の特徴的な画像所見を呈した1例と考えられた. 症例は81歳の女性.肺癌に対しNivolumab投与中に肝胆道系酵素上昇と腹部エコーで胆嚢壁肥厚を認め精査目的に当科紹介された.造影CTではび漫性に胆管および胆嚢に濃染する壁肥厚所見を認めたが胆嚢の緊満感はなく,肝内胆管拡張も認めなかった.EUSでは胆管および胆嚢のび漫性壁肥厚所見を認めたが狭窄所見は認めなかった.ERCP胆管像も狭窄所見は認めず,endoscopic nasobiliary drainage tube留置も肝胆道系酵素は改善しなかった.肝生検および胆管生検の病理所見では胆管上皮に好中球浸潤が目立っていたが,悪性所見は認めなかった.Nivolumabによる免疫関連性有害事象と判断しステロイドを投与し,肝胆道系酵素の改善および胆管と胆嚢壁肥厚所見の改善を認めた.Nivolumab関連胆管炎の特徴的な画像所見を呈した1例と考えられた. |
Author | 遠藤, 伸也 寺田, 修三 室, 博之 白根, 尚文 川口, 真矢 榎田, 浩平 佐藤, 辰宣 |
Author_FL | Satoh Tatsunori Terada Shuzo Muro Hiroyuki Endo Shinya Shirane Naofumi Kawaguchi Shinya Enokida Kohei |
Author_FL_xml | – sequence: 1 fullname: Satoh Tatsunori – sequence: 2 fullname: Kawaguchi Shinya – sequence: 3 fullname: Enokida Kohei – sequence: 4 fullname: Terada Shuzo – sequence: 5 fullname: Endo Shinya – sequence: 6 fullname: Shirane Naofumi – sequence: 7 fullname: Muro Hiroyuki |
Author_xml | – sequence: 1 fullname: 佐藤, 辰宣 organization: 静岡県立総合病院消化器センター肝胆膵内科 – sequence: 1 fullname: 遠藤, 伸也 organization: 静岡県立総合病院消化器センター肝胆膵内科 – sequence: 1 fullname: 寺田, 修三 organization: 静岡県立総合病院消化器センター肝胆膵内科 – sequence: 1 fullname: 室, 博之 organization: 静岡県立総合病院病理診断科 – sequence: 1 fullname: 榎田, 浩平 organization: 静岡県立総合病院消化器センター肝胆膵内科 – sequence: 1 fullname: 川口, 真矢 organization: 静岡県立総合病院消化器センター肝胆膵内科 – sequence: 1 fullname: 白根, 尚文 organization: 静岡県立総合病院消化器センター肝胆膵内科 |
BackLink | https://cir.nii.ac.jp/crid/1390001204350194432$$DView record in CiNii |
BookMark | eNo1UE1L5EAQbUTBWfXoP9hrZqu6O6ZzkkV2VRD3ouCt6aQ72kMmkcy4y97MDIgoKO5BwYuoiAfBi1fxz8T48S9sjXuoV1S9V4-q-kJGszwzhEwjtBEpwre-ynTeZrSNjI6QFgrBvBkRhKOkBSFyDyAIxslUr2cj8AUPOResRdaq8u7p_uZp-7oqb16GO8-351W5Vw12Xd-V9elFfVm-DK7qg9N6eFgN_tVHjjqpyrNl-ztPt7oqej2-eN2-bGafBwdVeYuPD_uTZCxRac9MfeYJsvrzx8rcgrf0a35x7vuS12EcqBfEAhUXJsRIo4-gRSSSmFORhIYziGKudRCCCrWfUKa10BEVLIi50CwxCtkE-dr4ZtbK2L4jshAAkAJnPqA7lFEnm29kXaNtrNI8S21mZCffKjK3ntR_8OOBkgIKCcBclkCpBPfOdxAMZnzkvnOabZw6vb5aN3KzsF1V_JWq6Ns4NbKxcUP4AS7-M_GGKmRHsTdhhJrn |
ContentType | Journal Article |
Copyright | 2018 日本胆道学会 |
Copyright_xml | – notice: 2018 日本胆道学会 |
CorporateAuthor | 静岡県立総合病院消化器センター肝胆膵内科 静岡県立総合病院病理診断科 |
CorporateAuthor_xml | – name: 静岡県立総合病院消化器センター肝胆膵内科 – name: 静岡県立総合病院病理診断科 |
DBID | RYH |
DOI | 10.11210/tando.32.132 |
DatabaseName | CiNii Complete |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | A case of nivolumab-induced cholangitis with diffuse wall thickening of the bile duct and gallbladder |
DocumentTitle_FL | A case of nivolumab-induced cholangitis with diffuse wall thickening of the bile duct and gallbladder |
EISSN | 1883-6879 |
EndPage | 138 |
ExternalDocumentID | 130006646939 dw1tando_2018_003201_022_0132_01383065145 article_tando_32_1_32_132_article_char_ja |
GroupedDBID | .LE ALMA_UNASSIGNED_HOLDINGS KQ8 MOJWN RJT RYH |
ID | FETCH-LOGICAL-j3402-7c81a48e91bd1510d8b8fc428f9e430bc4dd790a9d5f23dd8db2837c48d3fea13 |
ISSN | 0914-0077 |
IngestDate | Thu Jun 26 23:42:56 EDT 2025 Thu Jul 10 16:15:06 EDT 2025 Wed Sep 03 06:30:23 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 1 |
Language | Japanese |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-j3402-7c81a48e91bd1510d8b8fc428f9e430bc4dd790a9d5f23dd8db2837c48d3fea13 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/tando/32/1/32_132/_article/-char/ja |
PageCount | 7 |
ParticipantIDs | nii_cinii_1390001204350194432 medicalonline_journals_dw1tando_2018_003201_022_0132_01383065145 jstage_primary_article_tando_32_1_32_132_article_char_ja |
PublicationCentury | 2000 |
PublicationDate | 2018 |
PublicationDateYYYYMMDD | 2018-01-01 |
PublicationDate_xml | – year: 2018 text: 2018 |
PublicationDecade | 2010 |
PublicationTitle | Tando |
PublicationTitleAlternate | 胆道 |
PublicationTitle_FL | Journal of Japan Biliary Association J.J.B.A 胆道 |
PublicationYear | 2018 |
Publisher | 日本胆道学会 Japan Biliary Association |
Publisher_xml | – name: 日本胆道学会 – name: Japan Biliary Association |
References | 4) 小野薬品工業. オプジーボ インタビューフォーム. http://www.opdivo.jp/contents/pdf/open/interview.pdf 3) Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454 9) Gelsomino F, Vitale G, D'Errico A, et al. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 2017; 28: 671-672 5) Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2016; 2: 1346-1353 7) Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51-60 6) Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Canser Res 2015; 4: 560-575 2) 爲政大幾. ニボルマブ-効果と安全性について-. 皮膚臨床 2015; 57: 1647-1653 8) Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 2017. DOI: 10.1007/s10637-017-0453-0 1) Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 anti-bodies alone and in combination. Nat Rev Clin Oncol 2016; 13: 473-486 |
References_xml | – reference: 1) Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 anti-bodies alone and in combination. Nat Rev Clin Oncol 2016; 13: 473-486 – reference: 4) 小野薬品工業. オプジーボ インタビューフォーム. http://www.opdivo.jp/contents/pdf/open/interview.pdf – reference: 8) Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 2017. DOI: 10.1007/s10637-017-0453-0 – reference: 7) Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51-60 – reference: 5) Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2016; 2: 1346-1353 – reference: 2) 爲政大幾. ニボルマブ-効果と安全性について-. 皮膚臨床 2015; 57: 1647-1653 – reference: 3) Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454 – reference: 9) Gelsomino F, Vitale G, D'Errico A, et al. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 2017; 28: 671-672 – reference: 6) Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Canser Res 2015; 4: 560-575 |
SSID | ssib058494483 ssj0067390 ssib002671037 ssib002004169 ssib053391720 ssib002670270 ssib003171127 |
Score | 2.130307 |
Snippet | 症例は81歳の女性.肺癌に対しNivolumab投与中に肝胆道系酵素上昇と腹部エコーで胆嚢壁肥厚を認め精査目的に当科紹介された.造影CTではび漫性に胆管および胆嚢に濃染する... 要旨 : 症例は81歳の女性. 肺癌に対しNivolumab投与中に肝胆道系酵素上昇と腹部エコーで胆嚢壁肥厚を認め精査目的に当科紹介された. 造影CTではび漫性に胆管および胆嚢に... An 81-year-old woman, who was treated with nivolumab monotherapy, was referred to our department because of high levels of biliary tract enzymes, detected on... |
SourceID | nii medicalonline jstage |
SourceType | Publisher |
StartPage | 132 |
SubjectTerms | cholangitis cholecystitis immune-related adverse events Nivolumab 胆嚢炎 胆管炎 |
Title | び漫性に胆管および胆嚢壁肥厚像を呈したNivolumab関連胆管炎の1例 |
URI | https://www.jstage.jst.go.jp/article/tando/32/1/32_132/_article/-char/ja http://mol.medicalonline.jp/library/journal/download?GoodsID=dw1tando/2018/003201/022&name=0132-0138j https://cir.nii.ac.jp/crid/1390001204350194432 |
Volume | 32 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | 胆道, 2018/03/31, Vol.32(1), pp.132-138 |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1883-6879 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067390 issn: 0914-0077 databaseCode: KQ8 dateStart: 19870101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NaxQxFB9qBRFE_MSqlR7MqUyZmcxHcnNmO0tRLAgt9DbMJ7TgVrRF9NTdgohCRQ8KvYgt4qHQi1fxn1m3H_-Fv5eZnZ1CwY_DZl_ykpeX9ybJSyZ5o2l3ZcELy3NTvchtrtuOjHUZp6meZjKGNVKQ0UqnLebduUX7_pKzNHbmRePU0vpaMpO-PPVeyf9oFWnQK92S_QfN1kSRABj6RQgNI_wrHbOQwxJkAWehy4IW8wMChMF8r0JRimACsMtCj_kh880KJXwFWEyIBp06s8Okz3yLAF9hCWUx36EUERKWAKDaFR2pMktzRFAO2ZDt-WU1DsYJCyWTrqIsFav8NA49xVg4bEWIJJsFIRNB05peiDvZ6vCRUTlmmTSIHmr27WmCUCgwVCtAmY8yOyzwmJxVjWgDM02VyhZYVQCSrFFm8OsqdoBBLca0EjhoSkVIQnRNyn6bBX4zM_7axAABaKxs7rVUEwP1C6JKnDsKgD5bDdlIJUiu6M8SP0QM_PrN3VbT1sl1UjntlnONEFx3RfktneFkNNrsrTtdObOYFSavYuL0-Q8reDy1tAu1OsOtmbrUCZfi9AoTpqbtSi7PaGfRV12a0x48aqw8yRGb2_RE5xlWY2hHnG6YNqYGD5XXcSwiJEzjOj_MXGnbojaSXI-X259DuQzd39KNsib3MAxXsEwi_xcXHpevLksXMrAFO8vLDVtw4ZJ2sVrETfllj7ysja3EV7RzD6tjKle1pX73-8GPvYONb_3u3tHmq8P9L_3um37vNdIRHWzvDHa7R72vg63twea7fu_D4D1Qn_rdz3U3Of64c7yxW5Y97G31u_vmr59vr2mL7XChNadXnzDRV7gNW8NLhRnbIpdmksG2NjKRiCLFkr-QGBuNJLWzzJNGLDOnsHiWiSwhd1SpLTJe5LHJr2vjndVOfkObgp2duxBzklmp7ckYQjXzxLW83EwSizsTmiglFT0p_dRE1bgUKXlG3IpMFeA3xNDNzmglntDunZBtVI1xz6LsuVmWpt5AfoTxH8Hsj-gVLQWCYw1j2qh9EuqIIGWEWFWqHW7DpmMLUDy3bv4Bf0s7T1WUm5u3tfG1p-v5JMz9teSOejB_A1fzzls |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%81%B3%E6%BC%AB%E6%80%A7%E3%81%AB%E8%83%86%E7%AE%A1%E3%81%8A%E3%82%88%E3%81%B3%E8%83%86%E5%9A%A2%E5%A3%81%E8%82%A5%E5%8E%9A%E5%83%8F%E3%82%92%E5%91%88%E3%81%97%E3%81%9FNivolumab%E9%96%A2%E9%80%A3%E8%83%86%E7%AE%A1%E7%82%8E%E3%81%AE1%E4%BE%8B&rft.jtitle=Tando&rft.au=%E4%BD%90%E8%97%A4+%E8%BE%B0%E5%AE%A3&rft.au=%E5%B7%9D%E5%8F%A3+%E7%9C%9F%E7%9F%A2&rft.au=%E6%A6%8E%E7%94%B0+%E6%B5%A9%E5%B9%B3&rft.au=%E5%AF%BA%E7%94%B0+%E4%BF%AE%E4%B8%89&rft.date=2018&rft.pub=%E6%97%A5%E6%9C%AC%E8%83%86%E9%81%93%E5%AD%A6%E4%BC%9A&rft.issn=0914-0077&rft.eissn=1883-6879&rft.volume=32&rft.issue=1&rft.spage=132&rft.epage=138&rft_id=info:doi/10.11210%2Ftando.32.132&rft.externalDocID=130006646939 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0914-0077&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0914-0077&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0914-0077&client=summon |